Instrument Inactif

Communiqués Biosyent Inc. Toronto S.E.

Actions

BioSyent In-Licenses Endocrinology Product for Canada	12/06	GL
BioSyent Releases Financial Results for Q1 2024	17/05	GL
BioSyent Declares Second Quarter 2024 Dividend	17/05	GL
BioSyent Schedules Q1 2024 Earnings Release for May 16, 2024	09/05	GL
BioSyent to Attend Planet MicroCap Showcase	23/04	GL
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement	15/04	GL
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference	10/04	GL
FeraMAX® est la marque de supplément de fer que les pharmaciens et les médecins au Canada recommandent le plus souvent depuis neuf années consécutives	03/04	GL
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year	03/04	GL
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year	03/04	AQ
BioSyent to Present at LD Micro New York Investor Conference	01/04	GL
BioSyent Announces Grant of Restricted Share Units	27/03	GL
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023	13/03	GL
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023	13/03	AQ
BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024	06/03	GL
BioSyent Named to 2024 TSX Venture 50	21/02	GL
BioSyent Named to 2024 TSX Venture 50	21/02	AQ
BioSyent Declares First Quarter 2024 Dividend	06/02	GL
BioSyent Declares First Quarter 2024 Dividend	06/02	AQ
BioSyent Announces Renewal of Normal Course Issuer Bid	13/12	GL

Aucun résultat pour cette recherche